Urodynamix and Laborie Medical Expand Distribution Rights

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 22, 2008) - Urodynamix Technologies Ltd. ("Urodynamix") (TSX VENTURE: URO.V) today announced that it has amended its distribution agreement with Laborie Medical Technologies Inc. ("Laborie") to include worldwide non-exclusive sales, marketing and distribution rights for the Tetra(TM) Bladder Monitor System in the physician office and outpatient clinic markets in addition to the rights for the acute care setting previously granted.

Tetra is a non-invasive diagnostic medical device based on Urodynamix's near infrared spectroscopy (NIRS) technology. An accessory to Laborie's premium urodynamics systems, Tetra is used in conjunction with other non-invasive tests (including uroflowmetry and bladder ultrasound) to assess bladder function and aid in the diagnosis of LUTS. These symptoms are common in men with benign prostatic hyperplasia, or BPH (enlarged prostate), and Tetra provides clinicians with an alternative to more invasive, catheter-based procedures currently used to diagnose prostate obstruction and related conditions.

"This expansion of distribution rights demonstrates our commitment to our partnership with Laborie Medical, they were the first to market our NIRS product and conduct clinical trials with key opinion leaders," said Barry Allen, President and CEO of Urodynamix.

In May 2007, Urodynamix announced that it had entered into a worldwide licensing agreement with Laborie, the global market leader in urodynamics equipment and related products, to distribute uroNIRS technology in the acute care setting. The terms and conditions negotiated in the original agreement remain unchanged and apply to the amendment.

About Laborie Medical Technologies Inc.

Laborie was established in 1967 in Montreal, Quebec, Canada. The company is a global force in computerized Urodynamics processors and medically-related products. With more than 150 employees working in 4 offices and marketing units around the world, Laborie develops, manufactures and markets products in Urodynamics, Biofeedback & Stimulation, and Clinical Decision Support Systems.

As Laborie enters its 41st anniversary in business, it has established itself as 'the' supplier of pelvic floor assessment systems in many key academic centers. Laborie's AQUARIUS Wireless Urodynamic System is considered the benchmark diagnostic device for clinical trials and medical research. Laborie's product line includes urodynamic diagnostics, biofeedback/stimulation systems, compact ultrasound, computerized and physical bladder modeling tools, EMR solutions, consumables, as well as accredited education.

The network of installed users has afforded Laborie the opportunity to feed this network with new and exciting technology on a continuous basis. Recently, Laborie introduced the world's most compact, high resolution USB ultrasound system (NuWav(TM)), and it intends on providing Tetra(TM) technology in the same manner. Laborie has offices in Canada, USA, Belgium, China, UK and now Paris, France and San Paulo, Brazil. It has direct sales and distribution networks in 52 countries across North America, Europe, Asia and Oceania.

About Urodynamix Technologies Ltd.

Urodynamix is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contacts

Kuljeet Manj
Urodynamix Technologies Ltd.
Manager, Corporate Communications
(604) 638-0117
Email: kmanj@urodynamix.com
Website: www.urodynamix.com